GLP-1 RA use was associated with reduced risk of osteoarthritis in individuals with T2D, potentially through anti-inflammatory and weight-reducing mechanisms.
Joints protected tooGLP-1 drugs reduce osteoarthritis risk in diabetic patients — adding another benefit to their already extensive therapeutic profile
What the researchers found
GLP-1 RA use associated with reduced OA risk in T2D, likely through weight reduction and anti-inflammatory mechanisms.
Why it matters
Osteoarthritis affects millions of diabetic/obese patients. A drug that treats diabetes while protecting joints addresses two conditions simultaneously.
How the study worked
Cohort study evaluating GLP-1 RA use and incident osteoarthritis risk in T2D patients.
What this study cannot tell us
Observational. Cannot separate weight loss effects from direct anti-inflammatory joint effects.
How to read the evidence
Cohort study. Important new association.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs protect not just the heart, kidneys, and brain, but also the joints — comprehensive cardiometabolic-musculoskeletal benefit.
Questions still open
- Do GLP-1 drugs directly protect cartilage?
- Would GLP-1 drugs help existing osteoarthritis?
- Should joint health be a consideration in GLP-1 drug selection?
Common questions
Can GLP-1 drugs prevent arthritis?
Do they help existing arthritis?
Read the original research
Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study.
Diabetes research and clinical practice, 232, 113091
Citation
Jeon, Minjeong; Hong, Bin; Ko, Hwa Yeon; Song, Hong Ji; Kwak, Soo Heon; Kim, Ju Hwan; Shin, Ju-Young. (2026). Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study.. Diabetes research and clinical practice, 232, 113091. https://doi.org/10.1016/j.diabres.2026.113091